BCR and B-cell non-Hodgkin lymphoma: Although, ibrutinib has been widely studied for its role in targeting BCR signaling via BTK a few reports have also demonstrated a role of ibrutinib in regulating epigenetic modifications in B-cell lymphoma [11].